Trastuzumab is a monoclonal antibody targeted against the human epidermal growth factor
receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of …

Using 17,743 firm-year observations of industrial companies in 21 countries from 1991 to
1997, this paper finds that the use of accrual accounting (versus cash accounting) negatively …

… FTO, another m 6 A demethylase, upregulates PD-L1 expression in colon cancer cells,
although whether this reflects a direct effect on m 6 A modifications in PD-L1 mRNA is uncertain …

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy
in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate…

The phenotypic changes of increased motility and invasiveness of cancer cells are
reminiscent of the epithelial–mesenchymal transition (EMT) that occurs during embryonic …

Nuclear exclusion of the forkhead transcription factor FOXO3a by protein kinase Akt contributes
to cell survival. We investigated the pathological relationship between phosphoylated-…

… The HER-2/neu gene (also known as c-erbB2) encodes a transmembrane receptor tyrosine
kinase of relative molecular mass 185,000 (M r 185K) that shares partial homology with the …

… Lee for communicating results prior to publication; and M. Goulding and C. Kintner for … 1 h
at room temperature in 10 mM phosphate buffer containing 0.5 M NaCl, 3% BSA, O.3% Triton X…

… product of 1,260 amino acids that has a total M, of 139,221, significantly smaller than the
observed size of the neu gene product (M, = 185,000). Glycosylation accounts for 15,000 …

Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By
applying mass spectroscopy–based sequencing and reverse-phase protein arrays to 547 …